CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study
NCT06050330 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2026-01-23
Summary
Psoriasis is one of the commonest and most researched chronic immune-mediated inflammatory skin disorders that affects approximately 1-3% of the population worldwide and significantly impairs patients' quality of life. The most common form is plaque psoriasis, which makes up about 90% of cases, which primarily manifests as sharply demarcated, erythematous, scaly plaques, which can involve any part of the skin but most commonly the extensor surfaces (such as the elbows and knees) and the scalp. Apart from plaque psoriasis, there are also other clinical forms, such as guttate psoriasis (particularly common in children after strep throat infections), and pustular psoriasis (one of the most severe varieties of psoriasis, in which the spreading of pustules is generalized, with epidermal fulfillment and a severe general condition).
This disease is characterized by alternating severity and remission of disease symptoms, which include the formation of skin lesions of varying severity. The psoriasis area and severity index (PASI) is a widely used instrument in psoriasis trials that assesses and grades the severity of psoriatic lesions and the patient's response to treatment. It produces a numeric score ranging from 0 to 72. In general, a score of 5 to 10 is considered moderate disease, and a score over 10 is considered severe.
A series of basic and clinical studies have shown that psoriasis is mediated by components of both the innate and adaptive immune systems. The crosstalk between keratinocytes and various immune cells, especially helper T cells, plays a central role in the progression of psoriasis. Psoriasis is caused by chronic interaction between keratinocytes and activated immune cells. Numerous studies have established that hyperproliferation and abnormal differentiation of keratinocytes is a secondary phenomenon induced by immune activation. This "immune" hypothesis, is mainly based on dendritic cell (DC) and T cell pathogenic functions.The abnormal expression of S100A7 as a part of innate immunity in psoriasis vulgaris has been confirmed. S100 proteins are being discussed not only as potential biomarkers as well as new therapeutic targets through inhibition of S100 protein expression, targeted degradation, and antibody-mediated binding of S100 proteins. The most common therapeutic approaches include inhibition of S100 protein expression using microRNA-, small interfering RNA- or short hairpin RNA-based knockdown of S100 proteins using neutralizing antibodies or using specific small-molecule inhibitors. On the other side the role of CD4+ T cells (Th 17 cells) as a part of adaptive immunity, seems to be critical in the development of the skin lesions. Whether S100A7 or Th 17 cells are related to the severity of psoriasis is unclear. Immunohistology provides invaluable tools for better understanding psoriasis's pathogenetic mechanism and understanding the molecular processes involved in the pathogenesis of psoriasis.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
skin biopsy
Paraffin sections,5 Um thick will be prepared from the skin samples and will be analyzed for light microscopy
Sponsors & Collaborators
-
Sohag University
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-09-30
- Primary Completion
- 2024-09-30
- Completion
- 2024-09-30
Countries
- Egypt
Study Locations
More Related Trials
-
Differential Clinical and Serologic Response in Psoriasis and Psoriatic Arthritis to Drug Treatment
NCT00451243 ·Status: COMPLETED
-
Comparative Analysis of Small and Large Plaque Psoriasis
NCT01920906 ·Status: COMPLETED ·Phase: NA
-
Impact of COVID-19 on Psoriasis Practice
NCT04581044 ·Status: COMPLETED
-
Impact of COVID 19 on Psoriasis Patients
NCT05381402 ·Status: UNKNOWN
-
Evaluation The Effect of NB-UVB and Methotrexate on The Level of Serum Gelsolin in Psoriatic Patients
NCT06712238 ·Status: RECRUITING ·Phase: NA
-
Evaluation of Stigma Toward Patients With Alopecia Areata, Atopic Dermatitis, Vitiligo, and Psoriasis
NCT06801821 ·Status: RECRUITING
-
Association Between Biologic Therapy and Demodex Density in Psoriasis Patients: A Comparative Study
NCT05954572 ·Status: UNKNOWN
-
Evaluation of Desmoglein-3 Autoantibodies in the Tissues of Oral Lichen Planus and Correlation with Disease Severity
NCT06652477 ·Status: NOT_YET_RECRUITING
-
Pilot Studies Testing Levels of P63 in Psoriasis Skin Lesions
NCT04560647 ·Status: COMPLETED
-
The Effect of Psoriatic Arthritis on Female Sexual Dysfunction
NCT06370221 ·Status: NOT_YET_RECRUITING
-
Serum Granulysin Level as a Marker to Detect the Severity of Psoriasis
NCT03469219 ·Status: UNKNOWN
-
The Effect of NB-UVB on Interleukin-36 Levels in Psoriasis
NCT03526705 ·Status: UNKNOWN ·Phase: NA
-
ATG5 as a Serum Marker of Autophagy in Psoriatic Patient
NCT05279638 ·Status: UNKNOWN
-
A Pilot Study to Explore the Role of Gut Flora in Psoriasis
NCT04099979 ·Status: WITHDRAWN
-
Comparison of Scalp Microbiota of the Psoriasis and Seborrheic Dermatitis Patients
NCT03807453 ·Status: COMPLETED
-
A Case Control Study Evaluating the Prevalence of Non-Alcoholic Fatty Liver Disease Among Patients With Psoriasis
NCT00930384 ·Status: COMPLETED
-
Serum Level of IL31,33 and 36 in Egyptian Paients With Psoriasis
NCT04344574 ·Status: UNKNOWN
-
Dermoscopic Findings of Small Plaque Parapsoriasis and Patch Stage Mycosis Fungoides and Histopathological Correlation
NCT05433727 ·Status: COMPLETED
-
Excimer Light in Psoriasis
NCT05283876 ·Status: COMPLETED ·Phase: NA
-
Physician- vs Questionnaire-Based Screening for Psoriatic Arthritis in Psoriasis
NCT07298265 ·Status: RECRUITING
-
Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00794807 ·Status: COMPLETED ·Phase: PHASE4
-
A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks
NCT01098721 ·Status: COMPLETED ·Phase: PHASE2
-
Safety and Tolerability of Repeat Courses of IM Alefacept
NCT00233662 ·Status: COMPLETED ·Phase: PHASE3
-
Prevalence of Psoriasis and Vitiligo in Assiut Governorate, Egypt
NCT04039451 ·Status: UNKNOWN
-
Can We Miss Pigmented Lesions in Psoriasis Patients?
NCT01053819 ·Status: COMPLETED ·Phase: PHASE4